摘要 |
<p>It is intended to provide a drug comprising a combination of a dipeptidyl peptidase IV (DPPIV) inhibitor with biguanide characterized by potentiating the effect of activated glucagon-like peptide-1 (GLP-1) in blood and/or activated glucagon-like peptide-2 (GLP-2) in blood.</p> |